CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Neurobo Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Neurobo Pharmaceuticals Inc
200 BERKELEY ST., FL 19
Phone: (857) 702-9600p:857 702-9600 BOSTON, MA  02116  United States Ticker: NRBONRBO

Business Summary
NeuroBo Pharmaceuticals, Inc., formerly Gemphire Therapeutics Inc., is a clinical-stage biotechnology company. The Company is focused on developing pharmaceuticals to treat neurodegenerative disorders. The Company is addressing unmet needs in patients with Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease. The Company’s product candidate, NB-01, is targeting neuropathic pain with an indication in PDN. The Company also provides NB-02, which is an Alzheimer’s and tauopathies drug.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/202012/31/2019YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, CEO, Treasurer & Director MinaSooch
President, Chief Executive Officer, Interim Principal Financial Officer, Treasurer, Secretary, Dire Jeong GuKang 48 1/1/2020 1/1/2020
Chief Financial Officer Jeffrey S.Mathiesen
15 additional Officers and Directors records available in full report.

Business Names
Business Name
GEMP
NeuroBo Co., Ltd.
Neurobo Therapeutics, Inc.
NRBO

General Information
Number of Employees: 12 (As of 12/31/2019)
Outstanding Shares: 16,427,307 (As of 5/14/2020)
Shareholders: 59
Stock Exchange: NASD
Federal Tax Id: 472389984
Fax Number: (734) 293-0444


Copyright © 2020 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, May 28, 2020